Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest.

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight ↗

October 05, 2026

Via MarketBeat

Performance

52-Week Range 48.4% below 52-week high

27.70

21.9552W Low 53.6552W High

1 Week 5.5% below 1-week high

25.051W Low 29.321W High

Maze Therapeutics, Inc. - Common Stock (MAZE) traded between $21.95 and $53.65 over the past 52 weeks and last traded at $27.70, 48.4% below its 52-week high. Over the past week it ranged between $25.05 and $29.32.

Past 12 Months

+4.8%

+12.3%

-5.1%

+1.0%

-30.3%

-3.0%

1W +$1.27

1M +$3.03

3M -$1.48

6M +$0.28

YTD -$12.07

1Y -$0.87

MAZE was -3.0% over the past year, +1.0% over six months, -30.3% year to date, +4.8% in the last week.

12 Months vs Market

MAZE

-3.0%

DIA

+12.4%

SPY

+17.4%

QQQ

+23.9%

IWM

+13.7%

Over the past 12 months MAZE returned -3.0% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.7%.

Volume & Liquidity

903.7K

929.0K

576.9K

648.1K

YTD

671.6K

613.2K

MAZE's 3-month average daily volume is 576.9K.

More News

Gapping stocks in Tuesday's session ↗

September 22, 2026

Via Chartmill

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 ↗

September 11, 2026

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 09, 2026

Via Chartmill

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

September 02, 2026

Maze Therapeutics Announces Appointments to Its Board of Directors

August 13, 2026

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 11, 2026

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗

June 29, 2026

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗

June 05, 2026

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

May 27, 2026

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 12, 2026

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗

May 07, 2026

Maze Therapeutics Announces $150 Million Registered Offering

April 22, 2026

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗

April 04, 2026

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗

March 25, 2026

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 25, 2026

Via Chartmill

March 25, 2026

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

March 25, 2026

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗

March 21, 2026

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026